Medicus Pharma (MDCX) has submitted a clinical design to the United Arab Emirates Department of Health to non-invasively treat Basal Cell Carcinoma, or BCC, of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-limiting toxicities or serious adverse events. The company also has SKNJCT-003 Phase 2 clinical study currently underway in 9 clinical sites in the United States. The company is on track to complete an interim data analysis of SKNJCT-003 before the end of Q1 2025 and to submit its findings to the FDA as part of a package seeking a Type C meeting with the FDA in Q2 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Ltd Poised for Growth: Buy Rating Reaffirmed Amid Promising Developments and Upcoming Catalysts
- Promising Phase 2 Study and Innovative Approach Boost Confidence in Medicus Pharma Ltd.
- Medicus Pharma Advances Phase 2 BCC Clinical Study with FDA Submission Plans
- Medicus Pharma announces phase 2 study SKNJCT-003 underway
- Medicus Pharma Announces Equity Purchase Agreement and TSXV Delisting
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue